February 2022

COVID-19 Monoclonal Antibodies
Pharmacy Policy and Billing Guidance for Reimbursement

Effective September 14, 2021, NYS Medicaid will reimburse pharmacies for the administration or dispensing of COVID-19 therapeutics, including monoclonal antibodies (mAb), with no member cost sharing. The Ninth amendment to the Public Readiness and Emergency Preparedness Act (PREP Act) expands the scope of authority for licensed pharmacists to order and administer certain COVID-19 therapeutics to populations authorized by the Food and Drug Administration (FDA).

Policy for Coverage:

- The NYS Medicaid program will reimburse NYS Medicaid enrolled pharmacies for the administration and dispensing of COVID-19 therapeutics.
- A pharmacy will only be reimbursed for a dispensing fee if a COVID-19 therapeutic is dispensed, but not administered.
- A pharmacy will be reimbursed a dispensing fee and an administration fee if a COVID-19 therapeutic is dispensed and administered.
- The COVID-19 therapeutic must be approved or granted Emergency Use Authorization (EUA) through the FDA, and must be ordered and administered in accordance with the FDA approval or authorization.
- Evusheld (tixagevimab and cilavimab) must be prescribed for an individual patient by a physician, nurse practitioner, or physician assistant licensed or authorized under New York State law to prescribe monoclonal antibodies for prevention of COVID-19.
- Pharmacists must adhere to guidance in the PREP Act, for further information see the following: Fact Sheet Expanding Access to Therapeutics COVID-19 HHS PREP ACT Declaration: 9th Amendment.
- Prior authorization is not required.
- Providers are prohibited from charging Medicaid members a co-payment or any cost-sharing responsibility for COVID-19 therapeutics, consistent with other COVID-19 Medicaid guidance.

Code	Labeler Name	Procedure Name
M0220	AstraZeneca	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring
M0221	AstraZeneca	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse

		reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

The mAb must be approved or granted Emergency Use Authorization through the FDA and must be ordered and administrated in accordance with FDA approval or authorization. Evusheld (tixagevimab and cilavimab) must be prescribed for an individual patient by a physician, nurse practitioner, or physician assistant licensed or authorized under New York State law to prescribe monoclonal antibodies for prevention of COVID-19.

Additional Information

- For Medicaid Medical Billing information on COVID-19 therapeutics information can be found here: New York State (NYS) Medicaid Billing Guidance for COVID- 19 Testing and Specimen Collection and Therapeutics
- Information regarding obtaining COVID-19 therapeutics can be found here: COVID-19 Monoclonal Antibody mAb Therapeutics Information for Providers
- Additional information on the Public Health Emergency and COVID-19 Therapeutics can be found here: COVID-19 Monoclonal Antibody Therapeutics